Characterising phenotypically relevant intratumoural heterogeneity in high grade serous ovarian cancer.

被引：0
|
作者：
Fotopoulou, Christina
Cunnea, Paula
Rama, Nona R.
Wulandari, Ratri
Gorgy, Tommy
Gabra, Hani
Stronach, Euan A.
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] Ovarian Canc Act Res Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16569
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16569
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer
    Lambrechts, Sandrina
    Smeets, Dominiek
    Moisse, Matthieu
    Braicu, Elena Ioana
    Vanderstichele, Adriaan
    Zhao, Hui
    Van Nieuwenhuysen, Els
    Berns, Els
    Sehouli, Jalid
    Zeillinger, Robert
    Darb-Esfahani, Silvia
    Castillo-Tong, Dan Cacsire
    Lambrechts, Diether
    Vergote, Ignace
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 51 - 64
  • [42] A multi-sample study reveals the evolution and heterogeneity in high-grade serous ovarian cancer
    Wong, Siao-Han
    Doberstein, Kai
    Marme, Frederik
    Brors, Benedikt
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Methylation profiling of ovarian cancer shows prognostic heterogeneity of histological subtypes and high-grade serous
    Bodelon, Clara
    CANCER RESEARCH, 2017, 77
  • [44] Mathematical model quantifies the effect of novel combination therapies in high-grade serous ovarian cancer.
    Hautaniemi, Sampsa
    Kozlowska, Emilia
    Farkkila, Anniina
    Vallius, Tuulia
    Carpen, Olli
    Grenman, Seija
    Lehtonen, Rainer
    Hynninen, Johanna
    Hietanen, Sakari
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 121 - 121
  • [45] Clinical features of long-term survivors with advanced high-grade serous ovarian cancer.
    Barretina-Ginesta, Maria-Pilar
    Bague, Anna Carbo
    Bujons, Elisabet
    Fortian, Arola
    Fina, Claudia
    Pardo, Marta
    Melendez-Munoz, Cristina
    Cardenas, Laura
    Taltavull, Anna
    Sabate, Josep
    Darder, Esther
    Feliubadalo, Lidia
    Barretina, Jordi
    Brunet, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] The tumor immune microenvironment correlates with neoadjuvant chemotherapy response in high-grade serous ovarian cancer.
    Zhu, Lei
    Cao, Guangming
    Hua, Dingchao
    Cui, Lina
    Zhao, Xiaochen
    Wang, Shuzhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17605 - E17605
  • [47] A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer.
    Millstein, Joshua
    Budden, Timothy
    Anglesio, Michael
    Talhouk, Aline
    Beeghly-Fadiel, Alicia
    Berchuck, Andrew
    Chenevix-Trench, Georgia
    deFazio, Anna
    Fasching, Peter A.
    Gayther, Simon
    Garcia, Maria
    Goode, Ellen L.
    Henderson, Michelle
    Konecny, Gottfried E.
    Orsulic, Sandra
    Huntsman, David
    Bowtell, David
    Doherty, Jennifer
    Pharoah, Paul
    Ramus, Susan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Differential protein expression patterns in vaginal swabs of patients with high-grade serous ovarian cancer.
    Llaneza, Danielle C.
    Cornelison, Robert
    Petrova, Yuliya I.
    Dobbin, Zachary C.
    Maxwell, Larry
    Conrads, Thomas P.
    Landen, Charles N.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 90 - 90
  • [49] Targeting new links in the proteostasis network as novel therapies in high-grade serous ovarian cancer.
    Lighty, Kinzie
    Shin, Yonghyun
    Mesmer, Fahmi
    Nakshatri, Harikrishna
    Iwanicki, Marcin
    Mitra, Sumegha
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 66 - 66
  • [50] Encouraging responses with bevacizumab in recurrent low-grade serous ovarian cancer.
    Schmeler, K. M.
    Tao, X.
    Sun, C. C.
    Malpica, A.
    Deavers, M.
    Sood, A.
    Coleman, R. L.
    Bodurka, D. C.
    Kavanagh, J. J.
    Gershenson, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345